Year: 2023

Hong Kong, Nov. 02, 2023 (GLOBE NEWSWIRE) — Alpha Technology Group Limited (the “Company” or “Alpha”), an established cloud-based IT solution service provider in Hong Kong, today announced the closing of its initial public offering (the “Offering”) of 1,750,000 ordinary shares (the “Ordinary Shares”) at a public offering price of $4.00 per share for total gross proceeds of $7,000,000, before deducting underwriting discounts and other offering expenses. The Offering closed on November 2, 2023 and the Ordinary Shares began trading on the Nasdaq Capital Market on October 31, 2023, under the ticker symbol “ATGL”. The Company has granted the underwriters an over-allotment option, within 45 days from the closing date of the Offering, to purchase up to an additional 262,500 Ordinary Shares at the public...

PARIS and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the pricing of its previously announced global follow-on offering reserved to specified categories of investors, consisting of (i) an offering of 3,106,907 American Depositary Shares (“ADSs”), each representing one ordinary share, €0.03 nominal value per share (each an “Ordinary Share”), of the Company, in the United States (the “U.S. Offering”) at an offering price of $5.36 per ADS, and (ii) an offering of 2,492,223 Ordinary Shares, exclusively to “qualified investors” in Europe (including France) within the meaning of Article 2(e) of Regulation...

PARIS and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the pricing of its previously announced global follow-on offering reserved to specified categories of investors, consisting of (i) an offering of 3,106,907 American Depositary Shares (“ADSs”), each representing one ordinary share, €0.03 nominal value per share (each an “Ordinary Share”), of the Company, in the United States (the “U.S. Offering”) at an offering price of $5.36 per ADS, and (ii) an offering of 2,492,223 Ordinary Shares, exclusively to “qualified investors” in Europe (including France) within the meaning of Article 2(e) of Regulation...

‘Btab set to boost opportunities for US sellers, expanding lines with quality Australian goods’. SYDNEY, Australia, Nov. 02, 2023 (GLOBE NEWSWIRE) — Btab Ecommerce Group, Inc. (OTC: BBTT) (the “Company”) has unveiled its latest plans to support small and medium size businesses to flourish in the super-brand dominated niches, by leveraging the power of the Btab network to connect US resellers with Australian made product ranges. The move will see significant numbers of US-based resellers of all sizes provided with open access to a broad range of high-quality product lines from Australia, provided either through Btab manufacturing facilities or via partnerships with thousands of high-quality Australian providers. Recognized worldwide for in-demand health and beauty product lines, the plans will open up access to Australian product...

New Patents Further Reinforce the FIRDAPSE® (amifampridine) Intellectual Patent Portfolio CORAL GABLES, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that the Company has received notification by the United States Patent and Trademark Office (“USPTO”) that two additional patents covering FIRDAPSE® (amifampridine) Tablets 10 mg, were allowed and will be granted within the next two months. These new patents are for claims associated with the unique and novel, previously unknown, bioavailability of FIRDAPSE under fasting and fed conditions of dosing. FIRDAPSE...

Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models NEWTOWN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Onconova and collaborators will present a preclinical poster related to its lead program, narazaciclib, at the 65th American Society for Hematology Annual Meeting & Exposition (ASH), taking place in San Diego, California from December 9 to 12, 2023. “The poster that we and researchers from the Josep Carreras Leukaemia Research Institute in Barcelona, Spain are presenting at ASH 2023 shows that the study...

The English-language edition of the company Announcement no 13 – 2023 will be published 3rd of November 2023 at www.roblon.com.

PARIS, FRANCE, November, 2nd, 2023 – Information on the total number of voting rights and shares in Tarkett’s share capital as of October, 31, 2023 (Article L233-8-II of the French Commercial Code andArticle 223-16 of the General Regulation of the Autorité des marchés financiers)Date Total number of shares in the share capital Total number of voting rightsAs of October 31, 2023   65,550,281   Number of theoretical voting rights: 123 644 811  Number of exercisable voting rights: 123 626 252*  * After deduction of the treasury shares without voting rights. *** Investor Relations Contact investors@tarkett.com Media contacts Tarkett – communication@tarkett.com Brunswick – tarkett@brunswickgroup.com – Tel.: +33 (0) 1 53 96 83 83 About Tarkett With a history of 140 years, Tarkett is a worldwide leader in...

2 November 2023 Announcement no. 43Resolutions of the Extraordinary General Meeting of Pharma Equity Group A/S Pharma Equity Group A/S today held its Extraordinary General Meeting with the following results:  1)   Attorney Martin Allan Christensen from Accura Advokatpartnerselskab was elected as chairman at the extraordinary general meeting.  2)   The following new candidates were elected to the Board of Directors: (i) Omar S. Qandeel, and (ii) Martin Engell-Rossen. The Board of Director immediately thereafter constituted itself with Christian Vinding Thomsen as the Chairman of the Board of Directors and Martin Engell-Rossen as the Vice Chairman of the Board of Directors. The Board of Directors will thereafter consist of Christian Vinding Thomsen (Chairman), Martin Engell-Rossen (Vice Chairman), Omar S. Qandeel, Lars Gundorph and Peter...